MX2022003668A - Metodos y composiciones para el tratamiento de la retinopatia diabetica. - Google Patents
Metodos y composiciones para el tratamiento de la retinopatia diabetica.Info
- Publication number
- MX2022003668A MX2022003668A MX2022003668A MX2022003668A MX2022003668A MX 2022003668 A MX2022003668 A MX 2022003668A MX 2022003668 A MX2022003668 A MX 2022003668A MX 2022003668 A MX2022003668 A MX 2022003668A MX 2022003668 A MX2022003668 A MX 2022003668A
- Authority
- MX
- Mexico
- Prior art keywords
- diabetic retinopathy
- methods
- treating diabetic
- compositions
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente descripción proporciona métodos para tratar retinopatía diabética y enfermedades inflamatorias oculares con anticuerpos anti-ceramida y fragmentos de anticuerpo. También se proporcionan métodos para el tratamiento de sujetos que han recibido previamente tratamiento para retinopatía diabética. En algunas modalidades, la descripción proporciona además métodos para tratar retinopatía diabética con una sola dosis de un anticuerpo anti-ceramida o fragmento de unión al antígeno del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962907287P | 2019-09-27 | 2019-09-27 | |
PCT/US2020/053046 WO2021062355A1 (en) | 2019-09-27 | 2020-09-28 | Methods and compositions for treating diabetic retinopathy |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022003668A true MX2022003668A (es) | 2022-07-13 |
Family
ID=75162993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022003668A MX2022003668A (es) | 2019-09-27 | 2020-09-28 | Metodos y composiciones para el tratamiento de la retinopatia diabetica. |
Country Status (11)
Country | Link |
---|---|
US (2) | US10975169B1 (es) |
EP (1) | EP4034166A4 (es) |
JP (1) | JP2022549908A (es) |
KR (1) | KR20220092872A (es) |
CN (1) | CN114728061A (es) |
AU (1) | AU2020351804A1 (es) |
BR (1) | BR112022005678A2 (es) |
CA (1) | CA3152489A1 (es) |
IL (1) | IL291725A (es) |
MX (1) | MX2022003668A (es) |
WO (1) | WO2021062355A1 (es) |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
JP2008528010A (ja) | 2005-01-31 | 2008-07-31 | アブリンクス ナームローゼ フェンノートシャップ | 重鎖抗体の可変ドメイン配列を作出する方法 |
US8562993B2 (en) | 2007-05-06 | 2013-10-22 | Board Of Regents The University Of Texas System | Methods for treating GI syndrome and graft versus host disease |
JP6482525B2 (ja) * | 2013-03-15 | 2019-03-13 | メモリアル スローン ケタリング キャンサー センター | 高親和性抗gd2抗体 |
US10124008B2 (en) | 2014-06-23 | 2018-11-13 | Wisconsin Alumni Research Foundation | Use of inhibitors of acid sphingomyelinase to treat acquired and inherited retinal degenerations |
MX2017001686A (es) | 2014-08-07 | 2017-09-01 | Memorial Sloan Kettering Cancer Center | Anticuerpos anti-ceramida. |
WO2018048941A2 (en) * | 2016-09-08 | 2018-03-15 | The Board Of Trustees Of The Leland Stanford Junior University | Use of high affinity monoclonal antibody product binders to increase the duration of action of therapeutic monoclonal antibody products in a biologic tissue |
HRP20221335T1 (hr) * | 2017-11-30 | 2022-12-23 | Regeneron Pharmaceuticals, Inc. | Upotreba antagonista vegf za liječenje angiogenih očnih poremećaja |
-
2020
- 2020-01-24 US US16/752,469 patent/US10975169B1/en active Active
- 2020-09-28 MX MX2022003668A patent/MX2022003668A/es unknown
- 2020-09-28 KR KR1020227013417A patent/KR20220092872A/ko unknown
- 2020-09-28 EP EP20869510.6A patent/EP4034166A4/en active Pending
- 2020-09-28 US US17/763,989 patent/US20220348678A1/en active Pending
- 2020-09-28 CN CN202080080401.6A patent/CN114728061A/zh active Pending
- 2020-09-28 BR BR112022005678A patent/BR112022005678A2/pt unknown
- 2020-09-28 WO PCT/US2020/053046 patent/WO2021062355A1/en active Application Filing
- 2020-09-28 JP JP2022519436A patent/JP2022549908A/ja active Pending
- 2020-09-28 CA CA3152489A patent/CA3152489A1/en active Pending
- 2020-09-28 AU AU2020351804A patent/AU2020351804A1/en active Pending
-
2022
- 2022-03-27 IL IL291725A patent/IL291725A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20220348678A1 (en) | 2022-11-03 |
CN114728061A (zh) | 2022-07-08 |
KR20220092872A (ko) | 2022-07-04 |
EP4034166A1 (en) | 2022-08-03 |
JP2022549908A (ja) | 2022-11-29 |
WO2021062355A1 (en) | 2021-04-01 |
AU2020351804A1 (en) | 2022-04-14 |
US10975169B1 (en) | 2021-04-13 |
BR112022005678A2 (pt) | 2022-06-21 |
CA3152489A1 (en) | 2021-04-01 |
EP4034166A4 (en) | 2023-10-25 |
US20210095051A1 (en) | 2021-04-01 |
IL291725A (en) | 2022-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202004701B (en) | Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof | |
MX2020008882A (es) | Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1. | |
PH12016501120B1 (en) | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof | |
MX2019011117A (es) | Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos. | |
MX2020007406A (es) | Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo. | |
MX2021009041A (es) | Anticuerpo anti-pd-1, fragmento de union a antigeno del mismo y uso farmaceutico del mismo. | |
MX2021001143A (es) | Anticuerpo de union a il-4r humana, fragmento de union a antigeno y uso medico del mismo. | |
MX2020002750A (es) | Anticuerpo il-6r y fragmento de union a antigeno y uso medico. | |
ZA202202363B (en) | Antibodies against ilt2 and use thereof | |
MX2021010116A (es) | Anticuerpo anti-pd-l1 y uso de este. | |
MX2021008958A (es) | Proteínas de unión a antígeno del receptor gamma anti-il2. | |
MX2022001896A (es) | Formulaciones anti-c5 de alta concentracion. | |
CR20230128A (es) | Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos | |
MX2020006171A (es) | Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer. | |
MX2020012613A (es) | Composiciones y usos de las mismas para el tratamiento de enfermedades o afecciones. | |
MX2021007235A (es) | Tubulisinas y conjugados de proteina-tubulisina. | |
MX2020008718A (es) | Anticuerpos de union a bcma y usos de los mismos. | |
MX2018009264A (es) | Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos. | |
BR112022003811A2 (pt) | Tratamento de retinopatia diabética com fab anti vegf totalmente humano modificado pós tradução | |
MX2023015070A (es) | Anticuerpo anti-cd40, fragmento de union a antigeno y uso medico del mismo. | |
MX2023009681A (es) | Composiciones de anticuerpos anti-tl1a y metodos de tratamiento en el pulmon. | |
MX2023001776A (es) | Anticuerpos contra ilt2 y uso de los mismos. | |
MX2022015769A (es) | Tubulisinas y conjugados de proteina-tubulisina. | |
CR20220127A (es) | Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1 | |
MX2022001065A (es) | Anticuerpo anti-bcma, fragmento de union al antigeno y uso medico del mismo. |